
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Cancer Biology Series | Patience Agyiri Andoh</title>
  <style>
@media screen and (max-width: 600px) { body { padding: 1em; font-size: 1em; } h1 { font-size: 1.5em; } }
    body {
      font-family: 'Segoe UI', sans-serif;
      background-color: #fefcff;
      color: #333;
      padding: 3em 2em;
      line-height: 1.8;
      max-width: 800px;
      margin: auto;
    }
    h1 {
      color: #b88be1;
      font-size: 2em;
      border-bottom: 2px solid #eee;
      padding-bottom: 0.5em;
    }
    h3 {
      color: #6B46C1;
      margin-top: 1.5em;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #6B46C1;
      display: inline-block;
      margin-top: 2em;
      text-decoration: none;
    }
  </style>
</head>
<body>
  
       <section>
  <h1>Part 1: Foundations of Cancer</h1>

  <h2>What is Cancer?</h2>
  <p>
    Cancer is a group of diseases marked by uncontrolled cell growth and the ability of abnormal cells to invade nearby tissues and spread (metastasize) to distant organs. Unlike normal cells, cancer cells bypass growth control signals, resist cell death, and keep dividing without limit. These cells develop a set of traits known as the hallmarks of cancer (Roizen, 2012):
  </p>
  <ul>
    <li>Sustaining proliferative signaling</li>
    <li>Evading growth suppressors</li>
    <li>Resisting cell death</li>
    <li>Inducing angiogenesis</li>
    <li>Enabling replicative immortality</li>
    <li>Activating invasion and metastasis</li>
    <li>Reprogramming cellular metabolism</li>
    <li>Evading immune destruction</li>
  </ul>

  <h2>Cell Cycle and its Regulation</h2>
  <h3>a. Overview of the Cell Cycle</h3>
  <p>
    The cell cycle includes G1, S, G2, and M phases. In G1, the cell grows and prepares for DNA replication. It may enter a resting state (G0). In the S phase, DNA replication occurs. In G2, the cell continues to grow and prepares for mitosis. M phase consists of nuclear (karyokinesis) and cytoplasmic (cytokinesis) division resulting in two identical daughter cells (Sherr, 2000).
  </p>

  <h3>b. Key Regulatory Proteins and Complexes</h3>
  <p>
    Cyclins and CDKs regulate the cycle by phosphorylating proteins needed for progression (Sherr, 2000; Knudsen et al., 2022):
  </p>
  <ul>
    <li>Cyclin D–CDK4/6: G1 phase</li>
    <li>Cyclin E–CDK2: G1/S transition</li>
    <li>Cyclin A–CDK2: S phase</li>
    <li>Cyclin B–CDK1: G2/M transition</li>
  </ul>

  <h2>Checkpoints in the Cell Cycle</h2>
  <ul>
    <li><strong>G1/S Checkpoint:</strong> Blocks cycle if DNA is damaged; p53 activates p21 to inhibit CDKs; Rb suppresses E2F (Sherr, 2000; Duffy et al., 2011).</li>
    <li><strong>Intra-S Checkpoint:</strong> Temporarily pauses DNA synthesis upon damage.</li>
    <li><strong>G2/M Checkpoint:</strong> Ensures complete and accurate DNA replication; CHK1/CHK2 kinases involved.</li>
    <li><strong>Spindle Assembly Checkpoint:</strong> Prevents anaphase until chromosomes are properly attached (Sherr, 2000).</li>
  </ul>

  <h2>Tumor Suppressors and Oncogenes in Cell Cycle Regulation</h2>
  <h3>a. Tumor Suppressors</h3>
  <ul>
    <li><strong>p53:</strong> Pauses cycle, induces senescence/apoptosis upon damage (Duffy et al., 2011).</li>
    <li><strong>Rb:</strong> Inhibits early entry into S phase by controlling E2F (Sherr, 2000).</li>
  </ul>

  <h3>b. Oncogenes</h3>
  <ul>
    <li><strong>Cyclin D1:</strong> Overexpressed in breast cancer and lymphomas (Finn et al., 2009).</li>
    <li><strong>CDK4/6:</strong> Upregulated in glioblastomas and melanomas (Finn et al., 2009).</li>
  </ul>

  <h2>Cell Cycle Dysregulation in Cancer</h2>
  <ul>
    <li><strong>Loss of p53:</strong> Over 50% of cancers lack p53, causing unchecked damaged cell survival (Duffy et al., 2011).</li>
    <li><strong>Overactive CDK4/6:</strong> Promotes early S phase entry by hyperphosphorylating Rb (Sherr, 2000).</li>
    <li><strong>Excess Cyclin D:</strong> Accelerates G1 progression, common in breast and lymphatic cancers (Finn et al., 2009).</li>
  </ul>

  <h2>References</h2>
  <ol>
    <li>Duffy, M. J. et al. (2011). Clinical Proteomics. <a href="https://doi.org/10.1186/1559-0275-8-9" target="_blank">https://doi.org/10.1186/1559-0275-8-9</a></li>
    <li>Finn, R. S. et al. (2009). Breast Cancer Research. <a href="https://doi.org/10.1186/bcr2419" target="_blank">https://doi.org/10.1186/bcr2419</a></li>
    <li>Knudsen, E. S. et al. (2022). Cell Reports. <a href="https://doi.org/10.1016/j.celrep.2022.110448" target="_blank">https://doi.org/10.1016/j.celrep.2022.110448</a></li>
    <li>Roizen, M. (2012). Yearbook of Anesthesiology and Pain Management. <a href="https://doi.org/10.1016/j.yane.2012.02.046" target="_blank">https://doi.org/10.1016/j.yane.2012.02.046</a></li>
    <li>Sherr, C. J. (2000). PubMed. <a href="https://pubmed.ncbi.nlm.nih.gov/10919634" target="_blank">https://pubmed.ncbi.nlm.nih.gov/10919634</a></li>
  </ol>
</section>

        
  <a href="index.html">← Back to Home</a>
</body>
</html>
